메뉴 건너뛰기




Volumn 12, Issue 1, 2010, Pages

'Rac'-ing upstream to treat rheumatoid arthritis

Author keywords

[No Author keywords available]

Indexed keywords

RAC PROTEIN; RHO FACTOR; ANTIRHEUMATIC AGENT; RAC1 PROTEIN;

EID: 77955495466     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2924     Document Type: Editorial
Times cited : (4)

References (8)
  • 2
    • 75749092187 scopus 로고    scopus 로고
    • 'Go upstream, young man': lessons learned from the p38 saga
    • 10.1136/ard.2009.119479, 19995751
    • Hammaker D, Firestein GS. 'Go upstream, young man': lessons learned from the p38 saga. Ann Rheum Dis 2010, 69(Suppl 1):i77-i82. 10.1136/ard.2009.119479, 19995751.
    • (2010) Ann Rheum Dis , vol.69 , Issue.SUPPL. 1
    • Hammaker, D.1    Firestein, G.S.2
  • 3
    • 66049086274 scopus 로고    scopus 로고
    • Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies
    • 10.1002/art.24485, 19404957
    • Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009, 60:1232-1241. 10.1002/art.24485, 19404957.
    • (2009) Arthritis Rheum , vol.60 , pp. 1232-1241
    • Damjanov, N.1    Kauffman, R.S.2    Spencer-Green, G.T.3
  • 5
    • 67650093218 scopus 로고    scopus 로고
    • The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
    • 10.1002/art.24567, 19565475
    • Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009, 60:1895-1905. 10.1002/art.24567, 19565475.
    • (2009) Arthritis Rheum , vol.60 , pp. 1895-1905
    • Kremer, J.M.1    Bloom, B.J.2    Breedveld, F.C.3    Coombs, J.H.4    Fletcher, M.P.5    Gruben, D.6    Krishnaswami, S.7    Burgos-Vargas, R.8    Wilkinson, B.9    Zerbini, C.A.10    Zwillich, S.H.11
  • 6
    • 50149083752 scopus 로고    scopus 로고
    • Mammalian Rho GTPases: new insights into their functions from in vivo studies
    • 10.1038/nrm2476, 18719708
    • Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008, 9:690-701. 10.1038/nrm2476, 18719708.
    • (2008) Nat Rev Mol Cell Biol , vol.9 , pp. 690-701
    • Heasman, S.J.1    Ridley, A.J.2
  • 8
    • 75749107531 scopus 로고    scopus 로고
    • Kinetic analysis of synovial signaling and gene expression in animal models of arthritis
    • Fukushima A, Boyle DL, Corr M, Firestein GS. Kinetic analysis of synovial signaling and gene expression in animal models of arthritis. Ann Rheum Dis 2009,
    • (2009) Ann Rheum Dis
    • Fukushima, A.1    Boyle, D.L.2    Corr, M.3    Firestein, G.S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.